Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 4
1982 3
1983 3
1984 3
1985 11
1986 8
1987 6
1988 7
1989 14
1990 10
1991 7
1992 18
1993 22
1994 21
1995 21
1996 19
1997 48
1998 55
1999 70
2000 78
2001 57
2002 66
2003 103
2004 130
2005 173
2006 195
2007 227
2008 252
2009 273
2010 346
2011 394
2012 500
2013 612
2014 651
2015 814
2016 897
2017 961
2018 1133
2019 1324
2020 1618
2021 1833
2022 2140
2023 2232
2024 2545
2025 170

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,983 results

Results by year

Filters applied: . Clear all
Page 1
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators. Shen L, et al. Among authors: he z. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442766 Free PMC article. Clinical Trial.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: he z. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
The translatome of glioblastoma.
Cornelissen FMG, He Z, Ciputra E, de Haas RR, Beumer-Chuwonpad A, Noske D, Vandertop WP, Piersma SR, Jiménez CR, Murre C, Westerman BA. Cornelissen FMG, et al. Among authors: he z. Mol Oncol. 2024 Oct 17. doi: 10.1002/1878-0261.13743. Online ahead of print. Mol Oncol. 2024. PMID: 39417309 Free article.
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial.
Xu L, Su X, He Z, Zhang C, Lu J, Zhang G, Sun Y, Du X, Chi P, Wang Z, Zhong M, Wu A, Zhu A, Li F, Xu J, Kang L, Suo J, Deng H, Ye Y, Ding K, Xu T, Zhang Z, Zheng M, Xiao Y; RELARC Study Group. Xu L, et al. Among authors: he z. Lancet Oncol. 2021 Mar;22(3):391-401. doi: 10.1016/S1470-2045(20)30685-9. Epub 2021 Feb 12. Lancet Oncol. 2021. PMID: 33587893 Clinical Trial.
Electro-optically Modulated Nonlinear Metasurfaces.
He Z, Qu L, Wu W, Liu J, Jin C, Wang C, You J, Liu W, Bai L, Gu Z, Cai W, Ren M, Xu J. He Z, et al. Nano Lett. 2024 Nov 13;24(45):14215-14221. doi: 10.1021/acs.nanolett.4c03369. Epub 2024 Oct 29. Nano Lett. 2024. PMID: 39470354
Actively implementing an evidence-based feeding guideline for critically ill patients (NEED): a multicenter, cluster-randomized, controlled trial.
Ke L, Lin J, Doig GS, van Zanten ARH, Wang Y, Xing J, Zhang Z, Chen T, Zhou L, Jiang D, Shi Q, Lin J, Liu J, Cheng A, Liang Y, Gao P, Sun J, Liu W, Yang Z, Zhang R, Xing W, Zhang A, Zhou Z, Zhou T, Liu Y, Tong F, Wang Q, Pan A, Huang X, Fan C, Lu W, Shi D, Wang L, Li W, Gu L, Xie Y, Sun R, Guo F, Han L, Zhou L, Zheng X, Shan F, Liu J, Ai Y, Qu Y, Li L, Li H, Pan Z, Xu D, Zou Z, Gao Y, Yang C, Kou Q, Zhang X, Wu J, Qian C, Zhang W, Zhang M, Zong Y, Qin B, Zhang F, Zhai Z, Sun Y, Chang P, Yu B, Yu M, Yuan S, Deng Y, Zhao L, Zang B, Li Y, Zhou F, Chen X, Shao M, Wu W, Wu M, Zhang Z, Li Y, Guo Q, Wang Z, Gong Y, Song Y, Qian K, Feng Y, Fu B, Liu X, Li Z, Gong C, Sun C, Yu J, Tang Z, Huang L, Ma B, He Z, Zhou Q, Yu R, Tong Z, Li W; Chinese Critcal Care Nutrition Trials Group (CCCNTG). Ke L, et al. Among authors: he z. Crit Care. 2022 Feb 16;26(1):46. doi: 10.1186/s13054-022-03921-5. Crit Care. 2022. PMID: 35172856 Free PMC article. Clinical Trial.
Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.
Xu J, Luo Q, Huang Y, Li J, Ye W, Yan R, Zhou X, He Z, Liu G, Zhu Q. Xu J, et al. Among authors: he z. Emerg Microbes Infect. 2024 Dec;13(1):2429627. doi: 10.1080/22221751.2024.2429627. Epub 2024 Nov 26. Emerg Microbes Infect. 2024. PMID: 39530458 Free PMC article. Review.
17,983 results
You have reached the last available page of results. Please see the User Guide for more information.